🧵of 🔟 #pharmacotherapy take home messages from #ESCCongress 22
1️⃣ Post MI - polypill (asp+ACEi+statin) improves 2º CV prev (SECURE)
2️⃣Antihypertensives can be taken AM or PM - no difference (TIME)
3️⃣Neprilysin inhibition doesn't affect cognitive function in HF (PERSPECTIVE)
1️⃣ Post MI - polypill (asp+ACEi+statin) improves 2º CV prev (SECURE)
2️⃣Antihypertensives can be taken AM or PM - no difference (TIME)
3️⃣Neprilysin inhibition doesn't affect cognitive function in HF (PERSPECTIVE)
4️⃣ AHF, IV Acetazolamide + loop diuretics ➡️ better decongestion, ⬇️ hospital stay & discharge without residual volume overload. (ADVOR)
5️⃣ Dapagliflozin for patients with HFpEF / HFmrEF, and HFimpEF. (DELIVER)
6️⃣Allopurinol doesn't improve major CV outcomes in IHD. (ALL-HEART)
5️⃣ Dapagliflozin for patients with HFpEF / HFmrEF, and HFimpEF. (DELIVER)
6️⃣Allopurinol doesn't improve major CV outcomes in IHD. (ALL-HEART)
7️⃣ Adjusted-dose VKA (not rivaroxaban) should remain the standard of care in patients with RHD & AF. (INVICTUS).
8️⃣The LIFE-HF model, Personalised lifetime predection of treatment benefit in HFrEF.
#ESCCongress
8️⃣The LIFE-HF model, Personalised lifetime predection of treatment benefit in HFrEF.
#ESCCongress
9️⃣Milvexian (XIa inhibitor) shows potential to reduce the risk of ischaemic stroke in phase 2 trial.
(AXIOMATIC-SPP).
🔟Asundexian (XIa inhibitor) in acute MI (PACIFIC-AMI) and in those with recent noncardioembolic stroke (PACIFIC-STROKE).
Need phase 3 trials.
(AXIOMATIC-SPP).
🔟Asundexian (XIa inhibitor) in acute MI (PACIFIC-AMI) and in those with recent noncardioembolic stroke (PACIFIC-STROKE).
Need phase 3 trials.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
